caa a22 4500 469073624 CHVBK 20180323132928.0 cr unu---uuuuu 170328e19921101xx s 000 0 eng 10.1007/BF01789016 doi (NATIONALLICENCE)springer-10.1007/BF01789016 Interferon γ but not tumor necrosis factor α decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells [Elektronische Daten] [Yoshihiko Tomita, Hisami Watanabe, Hisashi Kobayashi, Tsutomu Nishiyama, Shoji Tsuji, Michio Fujiwara, Shotaro Sato] Summary: Human renal cell cancer (RCC) cell lines, ACHN and KRC/Y, with or without exposure to cytokines, were examined for their susceptibility to lymphokine-activated killer (LAK) cells. Flow-cytometric analysis demonstrated constitutional expression of class I antigen on both cell lines, which was enhanced by interferon α (IFNα), IFNγ and tumor necrosis factor α (TNFα). A 4-h51Cr-release cytotoxicity assay demonstrated that pretreatment of both cell lines with IFNγ or IFNα, but not with TNFα, decreased their susceptibility to LAK cells. IFNγ also decreased susceptibility to natural killer cells in a 16-h51Cr-release cytotoxicity assay. IFNγ treatment decreased the susceptibility of ACHN cells in a dose-dependent manner. "Cold”-target competition assay clearly showed that IFNγ- but not TNFα-pretreated cells compete less effectively than do untreated target cells. Pretreatment with IFNγ, however, increased expression of intercellular adhesion molecule-1 (ICAM-1) to a degree comparable to that with TNFα. Northern blot analyses using a 520-base-pair ICAM-1 cDNA as a probe demonstrated that more 3.3-kb mRNA is expressed in IFNγ- and TNFα-pretreated cells. These results suggest that IFNγ-treated RCC cell lines may reduce their ability to be recognized by LAK cells, and that IFN-induced protection of RCC cell lines against LAK cells may depend upon a mechanism independent of the expression of class I antigens or ICAM-1 on tumor cells. Springer-Verlag, 1992 MHC class I molecules nationallicence ICAM-1 nationallicence LAK cells nationallicence Tomita Yoshihiko Department of Urology, Niigata University School of Medicine, Japan aut Watanabe Hisami Department of Immunology, Niigata University School of Medicine, Asahimachi-1, 951, Niigata, Japan aut Kobayashi Hisashi Department of Neurology, Brain Research Institute, Niigata University Niigata, Japan aut Nishiyama Tsutomu Department of Urology, Niigata University School of Medicine, Japan aut Tsuji Shoji Department of Neurology, Brain Research Institute, Niigata University Niigata, Japan aut Fujiwara Michio Department of Immunology, Niigata University School of Medicine, Asahimachi-1, 951, Niigata, Japan aut Sato Shotaro Department of Urology, Niigata University School of Medicine, Japan aut Cancer Immunology, Immunotherapy Springer-Verlag 35/6(1992-11-01), 381-387 0340-7004 35:6<381 1992 35 262 https://doi.org/10.1007/BF01789016 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01789016 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tomita Yoshihiko Department of Urology, Niigata University School of Medicine, Japan aut NATIONALLICENCE 700 1- Watanabe Hisami Department of Immunology, Niigata University School of Medicine, Asahimachi-1, 951, Niigata, Japan aut NATIONALLICENCE 700 1- Kobayashi Hisashi Department of Neurology, Brain Research Institute, Niigata University Niigata, Japan aut NATIONALLICENCE 700 1- Nishiyama Tsutomu Department of Urology, Niigata University School of Medicine, Japan aut NATIONALLICENCE 700 1- Tsuji Shoji Department of Neurology, Brain Research Institute, Niigata University Niigata, Japan aut NATIONALLICENCE 700 1- Fujiwara Michio Department of Immunology, Niigata University School of Medicine, Asahimachi-1, 951, Niigata, Japan aut NATIONALLICENCE 700 1- Sato Shotaro Department of Urology, Niigata University School of Medicine, Japan aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/6(1992-11-01), 381-387 0340-7004 35:6<381 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer